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Background. The RANKL/RANK/OPG signaling pathway is crucial for the regulation of osteoclast activity and bone resorption
being activated in osteoporosis. The pathway has been also suggested to influence glucose metabolism as observed in chronic
low inflammation. Aim. To test whether systemic blockage of RANKL by the monoclonal antibody denosumab influences glucose
metabolism in osteoporotic women. Study Design.This is a prospective study on the effect of a subcutaneously injected single 60mg
dose of denosumab in 14 postmenopausal severe osteoporotic nondiabetic women evaluated at baseline and 4 and 12 weeks after
their first injection by an oral glucose tolerance test. Results. A single 60mg dose of denosumab efficiently inhibited serum alkaline
phosphatase while it did not exert any significant variation in fasting glucose, insulin, or HOMA-IR at both 4 and 12 weeks. No
changes could be detected in glucose response to the glucose load, Matsuda Index, or insulinogenic index. Nonetheless, 60mg
denosumab induced a significant reduction in the hepatic insulin resistance index at 4 weeks and in HbA1c levels at 12 weeks.
Conclusions. A single 60mg dose of denosumab might positively affect hepatic insulin sensitivity though it does not induce clinical
evident glucose metabolic disruption in nondiabetic patients.
1. Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risk
of fragility fractures which represent the main clinical con-
sequence of the disease. Osteoporosis is a metabolic bone
disease characterized by excessive osteoclast activity. The
differentiation and the activity of the osteoclasts are regu-
lated by the RANKL/RANK/OPG (osteoprotegerin) pathway.
RANKL (also known as TNFSF11) is a member of the tumor
necrosis factor (TNF) superfamily and, after ligation with
its cognate receptor RANK (also known as TNFRSF11a), is
a potent stimulator of nuclear factor-𝜅B (NF-𝜅B), mainly
expressed by the osteoclasts. The pool of circulating RANKL
is largely determined by the production within the bone
compartment [1], where osteocytes are the major supplier of
RANKL to osteoclast precursors. Increased RANKL activity
has been demonstrated in diseases characterized by exces-
sive bone loss such as osteoporosis [2]. The pivotal role
of the RANKL/RANK/OPG pathway in bone resorption
has rendered it a therapeutic target for osteoporosis. A
fully monoclonal human antibody raised against RANKL,
named denosumab, has been developed and demonstrated
to be effective in inhibiting the RANKL/RANK pathway
[3]. Denosumab has entered clinical practice providing an
antiresorptive drug for the treatment of postmenopausal
osteoporosis.
The RANKL/RANK pathway has been involved also in
the pathogenesis of insulin resistance: accumulating evi-
dences suggest that activation of the transcription factor NF-
𝜅B and the downstream inflammatory signaling pathways
systematically and in the liver are key events in the etiology
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2015, Article ID 352858, 5 pages
http://dx.doi.org/10.1155/2015/352858
2 International Journal of Endocrinology
of hepatic insulin resistance and 𝛽-cell dysfunction [4–7].
The RANKL and its receptor RANK have been shown to
be expressed in human liver tissue and pancreatic 𝛽-cells.
Binding of RANKL to RANK activates NF-𝜅B signaling in
hepatocytes, leading to cytokine production, Kupffer cell
activation, excess storage of fat, and manifestation of insulin
resistance [8].
Recently, serum soluble RANKL concentrations were
found to be associated with insulin resistance assessed as
homeostasis model assessment of insulin resistance (HOMA-
IR) andwith the number ofmetabolic syndrome components
clustering in an individual [8]. Downregulation of RANKL in
nutritional and genetic animal models of insulin resistance
and type 2 diabetes mellitus revealed a marked improve-
ment in hepatic insulin sensitivity and amelioration or even
normalization of glucose concentrations and tolerance and
insulin signaling [8].
Therefore, postmenopausal osteoporotic women treated
with the anti-RANKL monoclonal antibody denosumab
might provide a human model investigating the effect of the
RANKL/RANK pathway blockage on glucose metabolism.
The aim of the present study was to investigate the effect
of the systemic blockage of the RANK-RANKL signaling
pathway by a single 60mg dose of denosumab on glucose
tolerance and insulin sensitivity in nondiabetic severe osteo-
porotic postmenopausal women.
2. Materials and Methods
2.1. Patients. Fourteen postmenopausal severe osteoporotic
Italian womenwere consequently enrolled at the Endocrinol-
ogy Unit of Policlinico San Donato. Clinical data are pre-
sented in Table 1. All patients met the criteria for reimburse-
ment of the treatment with 60mg denosumab every 25 weeks
according the Italian “nota 79”: 9 patients were affected with
at least one vertebral fracture, 1 patient was affected with a
hip fracture, and 4 patients were affected with neck 𝑇-score
< −3.0 SD and a wrist fracture and/or had age of menopause
earlier than 45 years and/or parents with fragility fractures.
Patients were supplemented with calcium 500mg/die and
cholecalciferol 800UI/die.
Exclusion criteria included active smoking, alcohol abuse,
overt diabetes, secondary osteoporosis, concomitant gluco-
corticoid treatment, kidney failure, liver or heart failure,
malignancies, treatmentwith drugs known to reduceRANKL
activity (metformin, thiazolidinediones, and angiotensin-
receptor blockers), and ongoing treatment with denosumab.
All the enrolled patients gave their written informed
consent and the study was approved by the local ethical
committee.
2.2. Study Design. This was a prospective study in patients
never previously treated with denosumab. Patients were
clinically and biochemically evaluated at baseline and 4 and
12 weeks after the first subcutaneously administrated 60mg
dose of denosumab: anthropometric measures (body weight,
height) were recorded; bone metabolism was investigated by
measurement of serum calcium, albumin, phosphate, total
alkaline phosphatase (ALP), PTH, and 25-hydroxyvitamin
D (25OHD) on blood samples collected after an overnight
fasting. serum calcium, phosphate, and albumin were mea-
sured according to routinely used laboratory kits. SerumPTH
was assayed by electrochemiluminescence on an Elecsys 2010
(Roche Diagnostics, Mannheim, Germany), while serum
25OHD was assayed by a chemiluminescent assay (LIAISON
test, DiaSorin Inc., Stillwater, MN, USA). Albumin-corrected
calcium was calculated according the following formula:
serum calcium (mg/dL) − 0.8 ∗ [4.0 – albumin (g/dL)].
2.3. Oral Glucose Tolerance Test (OGTT). All the participants
underwent a 75 g OGTT test after a 12-hour overnight fast.
OGTT was performed according to a standardized protocol.
Fasting blood samples were collected before administration
of 75 g glucose solution, which was consumed within 5min.
Additional blood samples were drawn at 0, 30, 60, 90, and 120
minutes for the determination of plasma glucose and serum
insulin levels. All patients were restricted from eating and
drinking during the testing period. Glucose tolerance status
at baseline (normal glucose tolerance (NGT): fasting plasma
glucose (FPG)< 110mg/dL and 2 h-PG< 140mg/dL; impaired
glucose tolerance (IGT): FPG < 126mg/dL, 140mg/dL < 2 h-
PG < 200mg/dL; type 2 diabetes: FPG ≥ 126mg/dL, 2 h-PG ≥
200mg/dL) was defined according to the ADA 1997 criteria
[9]. All patients were tested byOGTT at baseline and 4 and 12
weeks after the first single 60mg dose of denosumab. Plasma
glucose levels were measured using the glucose oxidase
method (Roche Diagnostic Gmbh, Mannheim, Germany).
Insulin levels were measured using chemiluminescence assay
(ECLIA, Roche Diagnostic Gmbh, Mannheim, Germany).
HbA1c was measured by a turbidimetric inhibition assay
(TINIA, Roche Diagnostic Gmbh, Mannheim, Germany).
We estimated the glucose response to the oral glucose
load by calculating the ΔAUC (area under the curve) of
glucose using the trapezoidal integration rule. We further
assessed the insulin sensitivity from the OGTT according to
the commonly used surrogate marker Matsuda index [10],
including plasma glucose and serum insulin taken at 0, 30,
60, 90, and 120min during the OGTT. First-phase insulin
secretion (𝛽-cell function) was estimated from the OGTT by
the method of the insulinogenic index, modeling the change
in serum insulin divided by the change of plasma glucose
from 0 to 30min [11]. We also estimated hepatic insulin
resistance index (HIRI) by AUCG0–30 × AUCI0–30, where
AUC is the total area under the curve of glucose and insulin,
respectively, in the interval between 0 and 30min. AUCswere
estimated using the trapezoidal integration rule and with
glucose, insulin, and time expressed as mg/dL, mUI/mL, and
minutes, respectively [12].
2.4. Statistical Analysis. Data are presented as mean ± SD.
Continuous variables evaluated at baseline and at 4 and 12
weeks were compared by ANOVA. 𝑃 levels < 0.05 were
considered statistically significant. Variables with nonnormal
skewed distribution (calculated ΔAUC glucose and HIRI
values) were logarithmically transformed before analysis.
Statistical analysis was performed by theWinstat Statistics for
Microsoft Excel 2007.
International Journal of Endocrinology 3
Table 1: Clinical and biochemical features of patients treated with denosumab at baseline and at 4 and 12 weeks after denosumab injection.
Parameters Baseline 4 weeks 12 weeks 𝑃
𝑛 14 14 14
Age, years 67.1 ± 11.6
BMI, kg/m2 24.8 ± 3.7 24.5 ± 4.3 24.8 ± 4.1 ns
Bone metabolic parameters
Serum calcium∗, mg/dL 9.6 ± 0.6 9.1 ± 0.4 9.0 ± 0.3 0.01
Serum phosphate, mg/dL 3.4 ± 0.3 3.1 ± 0.5∗ 3.2 ± 0.6 0.02∗
Total ALP, UI/L 81.6 ± 26.8 72.7 ± 24.4 53.2 ± 14.1 0.001
PTH, pg/mL 59.1 ± 34.1 89.4 ± 59.6 74.8 ± 36.6 ns
Serum 25OHD∗∗, ng/dL 26.9 ± 6.5 30.6 ± 10.5 34.6 ± 7.7 ns
L1-L4 𝑇-score −3.3 ± 1.5
Neck 𝑇-score −2.3 ± 1.0
Femur 𝑇-score −2.2 ± 1.0
Glucose metabolic parameters
Serum glucose, mg/dL 91.4 ± 10.1 89.6 ± 14.1 92.1 ± 15.3 ns
Serum insulin, 𝜇UI/mL 9.5 ± 6.7 8.5 ± 5.5 10.5 ± 10.1 ns
HOMA-IR∘ 2.2 ± 1.7 2.0 ± 1.4 2.7 ± 3.1 ns
HbA1c, mmol/mol 37.6 ± 5.4 37.8 ± 4.2 36.4 ± 5.6§ 0.04§
logΔAUC glucose∧, mg/dL∗min 2.8 ± 2.8 2.8 ± 2.7 2.7 ± 2.7 ns
Matsuda index 5.3 ± 3.0 5.8 ± 3.2 6.6 ± 4.7 ns
Insulinogenic index 0.9 ± 0.8 0.5 ± 0.4 0.8 ± 0.6 ns
log HIRI∘∘ 6.6 ± 6.5 6.4 ± 6.3# 6.6 ± 6.7 0.01#
∗Albumin-corrected calcium; ∗∗25-hydroxyvitamin D; ∘homeostasis assessment model of insulin resistance; ∧Δ of area under the curve of glucose; ∘∘hepatic
insulin resistance index; ns: not significant.
3. Results
3.1. Effects of the Single 60mg Dose of Denosumab on Bone
Metabolism. All patients were tested in conditions of vitamin
D sufficiency (serum 25OHD > 20 ng/mL); mean serum
25OHD levels did not vary at 4 and 12 weeks (Table 1).
A single subcutaneously (sc) administered 60mg dose of
denosumab induced significant decreases in mean serum
albumin-corrected calcium (9.6 ± 0.6 versus 9.1 ± 0.4mg/dL;
𝑃 = 0.01), phosphate (3.4 ± 0.3 versus 3.1 ± 0.5mg/dL;
𝑃 = 0.02), and ALP levels (81.6 ± 26.8 versus 72.2 ±
24.4UI/L; 𝑃 = 0.001) at 4 weeks (Table 1). Concomitantly,
an increase in mean serum PTH level was detected though
it was not statistically significant (89.4 ± 59.6 versus 59.1 ±
34.1 pg/mL at baseline, 𝑃 = 0.08). At 12 weeks from the single
dose subcutaneous injection,mean serumalbumin-corrected
calcium level was significantly reduced (9.0 ± 0.3mg/dL;
𝑃 = 0.01 versus baseline), while mean serum ALP level
was further decreased determining an inhibition of 35% of
the basal level (53.2 ± 14.1UI/L; 𝑃 = 0.001 versus baseline;
Table 1). Mean serum phosphate and PTH levels returned to
basal levels (3.2 ± 0.6mg/dL and 74.8 ± 36.6 pg/mL, resp.).
3.2. Effects of the Single 60mg Dose of Denosumab on Glucose
Metabolism. Mean fasting plasma glucose and serum insulin
levels were unaffected after 1 and 3 months from a single
60mg dose of denosumab administration (Table 1). OGTT at
basal evaluation diagnosed 4 patients with impaired glucose
tolerance (IGT) and 1 patient with diabetes. At 4 and 12 weeks
from denosumab administration, the prevalence and the
diagnosis of the glucose alterations were unchanged. Insulin
resistance was evaluated by HOMA-IR calculation: at base-
line, HOMA-IR was higher than 2.5 in 5 of 14 patients and
the administration of the single 60mg dose of denosumab
did not change the prevalence of HOMA-IR impairment in
the studied group. Moreover, mean HOMA-IR values did
not vary significantly at 4 and 12 weeks after denosumab
administration (2.2±1.7 at baseline versus 2.0±1.4 at 4 weeks
versus 2.7 ± 3.1 at 12 weeks, 𝑃 = NS).
Considering the parameters derived from the OGTT, the
mean AUCs of glucose levels after the oral glucose load,
exploring the variations of plasma glucose in response to the
glucose load, did not show significant differences between
baseline and 4 and 12 weeks (Table 1). The whole body
insulin resistance Matsuda index did not vary from baseline
(5.3 ± 3.0) to 4 weeks (5.8 ± 3.2) and to 12 weeks after
single 60mg dose of denosumab (6.6 ± 4.7). Similarly, the
insulinogenic index, exploring the defect in insulin secretion,
was unaffected by the administration of a single 60mg dose
of denosumab (0.9 ± 0.4 at baseline versus 0.5 ± 0.4 at 4
weeks versus 0.8 ± 0.6 at 12 weeks; 𝑃 = NS). Calculation of
the hepatic insulin resistance index, which has been demon-
strated to selectively quantitate hepatic insulin resistance
in nondiabetic subjects [12], showed that a single 60mg
dose of denosumab significantly reduced the hepatic insulin
resistance after 4 weeks since its administration (log HIRI:
6.6 ± 6.5 versus 6.4 ± 6.3, 𝑃 = 0.01). The sample size, though
small, was sufficient to detect a significant difference between
4 International Journal of Endocrinology
baseline and 4-week HIRI values in the present patient series.
Indeed, the reduction could not be further detected after 12
weeks (log HIRI 6.6 ± 6.7). Finally, circulating HbA1c levels
showed a trend towards reduction between baseline and 4-
week evaluation (37.6 ± 5.4 and 37.8 ± 4.2mmol/mol, resp.)
and 12 weeks after the injection (36.4 ± 5.6mmol/mol; 𝑃 =
0.04).
4. Discussion
Denosumab is a potent, targeted, and reversible inhibitor of
bone resorption. Its clinical efficacy in increasing the bone
mineral density in postmenopausal women and reducing
the risk of vertebral, nonvertebral, and hip fractures is
demonstrated up to 8 years of treatment [13]. Denosumab
is a fully human monoclonal antibody that binds with high
specificity to human RANKL, which plays an essential role
in mediating bone resorption through osteoclast formation,
function, and survival. Recently, the effect of RANKL has
been investigated on insulin sensitivity and glucose home-
ostasis in animalmodels of insulin resistance anddiabetes [8].
High serum concentrations of soluble RANKL are associated
with increased bone resorption and bone loss, which can
lead to osteoporosis [14]. Besides this, circulating RANKL
levels emerged also as an independent risk predictor of type 2
diabetesmellitus development.Moreover, systemic or hepatic
blockage of RANKL signaling in genetic and nutritional
mousemodels of type 2 diabetesmellitus resulted in amarked
improvement of hepatic insulin sensitivity and amelioration
or even normalization of plasma glucose concentrations and
glucose tolerance [8].
Based on this experimental observation, we tested
whether denosumab administration could affect glucose
metabolism in postmenopausal severe osteoporotic women.
Here, we presented the results of a prospective study inves-
tigating the effect of a single subcutaneously injected 60mg
dose of denosumab in patients never previously treated with
denosumab. Patients were evaluated at 4 weeks after injection
when circulating concentrations of denosumab reach their
maximal levels and at 12 weeks when circulating denosumab
levels showed variable decreases even up to 10-fold the
maximal levels [15].
As expected, the subcutaneous administration of a single
60mg dose of denosumab induced significant decreases in
the serum ALP levels confirming the bone antiresorptive
effect of denosumab. As previously reported [16], serum
albumin-corrected calcium decreased though none of the
patients experienced hypocalcemia, while plasma PTH levels
tended to increase. A single 60mg dose of denosumab did
not have a clinically important effect on fasting glucose and
insulin as well as the response of plasma glucose to the
glucose load. When we looked at specific aspects of glu-
cose metabolism by means of validated surrogated markers
derived from fasting glucose and from OGTT, we could not
detect any significant effect on the hepatic insulin resistance
index HOMA-IR and on the whole body insulin resistance
marker Matsuda index, though mean Matsuda index values
at 4 and 12 weeks showed a trend to increase with respect
to baseline. Similarly, 60mg denosumab did not affect the
insulin secretion as suggested by undetectable changes of the
insulinogenic index values. Nonetheless, whenwe specifically
considered hepatic insulin resistance by calculating the index
HIRI validated by Abdul-Ghani et al. [12] in nondiabetic
subjects, HIRI valueswere significantly reduced after 4weeks.
HIRI derived from plasma glucose and insulin concen-
trations during the OGTT correlates more strongly with
the index derived from the euglycemic-hyperinsulinemic
clamp compared to the HOMA-IR, likely because HIRI takes
into consideration both the basal measurement of hepatic
glucose production and the suppression of hepatic glucose
production during theOGTT [12].The early glucose response
during OGTT provides an index of hepatic resistance to
insulin with a great selectivity in detecting changes in hepatic
insulin sensitivity.The detection of reduced HIRI values after
4 weeks from denosumab injection was in agreement with
the reduction of the hepatic insulin resistance reported in
the animal models with blockage of the RANKL signaling
[8]. Indeed, the improvement of hepatic insulin sensitivity
detected at 4 weeks could not be confirmed at 12 weeks:
this pattern might be related to the nonlinear pharmacoki-
netics of denosumab whose circulating concentrations were
declining after 12 weeks from the subcutaneous injection [15].
Nonetheless, it was of interest to notice that mean HbA1c
levels were significantly lower at 12 weeks compared with
the circulating levels measured at baseline and at 4 weeks.
Therefore, the results of our short-term investigation suggest
a positive though not clinically relevant effect of denosumab
on hepatic resistance to insulin in nondiabetic osteoporotic
women.
A previous study explored the effect of antiresorptive
drugs on glucose metabolism: authors revised in a post
hoc analysis data from three randomized, placebo-controlled
trials in osteoporotic postmenopausal women treated with
antiresorptive drugs among which there was the fracture
reduction evaluation of denosumab in osteoporosis every
6 months (FREEDOM) trial to test whether antiresorptive
therapies result in higher fasting glucose or greater diabetes
incidence. Over a period of 3 years, no significant changes in
fasting glucose and diabetes incidence were detected between
the FREEDOM cohort and its control group [17]. These
data were not in contrast with the present report as we
similarly could not detect clinical relevant impairment of
fasting glucose and insulin levels.
Admittedly, the present study provided preliminary data
that warrant further investigation. The main limits are the
small size of the sample and the lack of a control group
treated with placebo. Indeed, such a control group may be
considered not ethically advisable as all the patients enrolled
suffered from severe osteoporosis complicated with frailty
fractures and with a high risk of fracture that unequivocally
need to be treated. It would be of interest also to examine
the effect of denosumab in severe osteoporotic women with
overt type 2 diabetes to test whether denosumab treatment
might improve glycemic control by reducing hepatic insulin
resistance. Nonetheless, our data support the link between
inflammation anddisrupted glucose homeostasis through the
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proinflammatory nuclear factor-𝜅B (NF-𝜅B) transcriptional
program [18].
In conclusion, in postmenopausal severe osteoporotic
women, the blockade of RANKLby a single dose 60mg deno-
sumab (1) efficiently inhibits the bone resorption marker, (2)
does not affect glucose homeostasis at clinical level, and (3)
improves hepatic insulin sensitivity in nondiabetic patients.
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